Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Tumor Burden—
- High Tumor Burden—
The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria calculates determining thromboembolic risk, heparin-induced thrombocytopenia probability, and bleeding diathesis. Key inputs include tumor mass over 7cm. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance
Clinical Indication
The Groupe d'Etude des Lymphomes Folliculaires (GELF) Criteria is indicated for bedside clinical practice to support Determines if immediate therapy for follicular lymphoma is needed by identifying high tumor burden patients requiring treatment rather than active surveillance. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Originally developed by the Groupe d'Etude des Lymphomes Folliculaires to standardize treatment decisions in follicular lymphoma.
Positive if any one or more of the following criteria are present: tumor mass >7cm, ≥3 nodal sites >3cm, B symptoms, splenic enlargement below umbilical line, compression syndrome, serous effusion, leukemic phase >5.0×10⁹/L, granulocytes <1.0×10⁹/L, or platelets <100×10⁹/L
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| tumor_mass_over_7cm | string | Yes | Any nodal or extranodal tumor mass > 7 cm diameter |
| three_or_more_nodal_sites | string | Yes | Involvement of ≥3 nodal sites, each > 3 cm diameter |
| systemic_b_symptoms | string | Yes | Presence of systemic or B symptoms (fever, night sweats, weight loss) |
| splenic_enlargement | string | Yes | Splenic enlargement with inferior margin below umbilical line |
| compression_syndrome | string | Yes | Compression syndrome (ureteral, orbital, gastrointestinal) |
| serous_effusion | string | Yes | Pleural or peritoneal serous effusion |
| leukemic_phase | string | Yes | Leukemic phase: > 5.0 x 10⁹/L circulating malignant cells |
| granulocyte_count_low | string | Yes | Granulocyte count < 1.0 x 10⁹/L |
| platelet_count_low | string | Yes | Platelet count < 100 x 10⁹/L |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| — | Low Tumor Burden | Active surveillance appropriate |
| — | High Tumor Burden | Immediate therapy recommended |
Evidence-Based References (EBM)
- Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. J Clin Oncol. 1997;15(3):1110-1117. doi: 10.1200/JCO.1997.15.3.1110DOI: 10.1200/JCO.1997.15.3.1110
- Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258-1265. doi: 10.1182/blood-2003-12-4434DOI: 10.1182/blood-2003-12-4434
- Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516-522. doi: 10.1016/S0140-6736(03)14110-4DOI: 10.1016/S0140-6736(03)14110-4